Feb 4, 2026 06:54AM

Nov 12, 2025 07:43AM

Nov 7, 2025 04:45PM

Nov 3, 2025 12:04AM

Oct 27, 2025 06:44AM

Oct 20, 2025 02:52PM

Oct 20, 2025 02:27PM Replimune (REPL) call put ratio 1.2 calls to 1 put as share price up 105%

Oct 20, 2025 10:20AM

Oct 20, 2025 10:02AM

Oct 20, 2025 08:59AM

Oct 20, 2025 07:02AM

Sep 19, 2025 06:51AM

Sep 19, 2025 02:13AM

Sep 18, 2025 09:15AM Replimune meets with FDA on melanoma treatment application

Sep 9, 2025 06:50AM

Sep 2, 2025 08:02AM

Aug 11, 2025 05:30AM

Jul 31, 2025 02:12PM

Jul 31, 2025 05:01AM

Jul 30, 2025 01:43PM

Jul 30, 2025 10:03AM Increasing unusual option volume: REPL CP PGEN CRDF LC INDA NEO TTI JBS HOG TER

Jul 29, 2025 03:19PM

Jul 23, 2025 06:06AM

Jul 23, 2025 06:00AM

Jul 23, 2025 12:29AM

Jul 22, 2025 04:31PM

Jul 22, 2025 01:19PM

Jul 22, 2025 12:31PM Leerink Partners Reiterates Outperform Rating on Replimune Group (REPL), PT $21, 'Estimates Under Review'

Jul 22, 2025 11:18AM

Jul 22, 2025 10:30AM

Jul 22, 2025 09:50AM

Jul 22, 2025 09:15AM

Jul 22, 2025 09:09AM

Jul 22, 2025 08:53AM

Jul 22, 2025 08:52AM Mizuho Desk Comments on Replimune (REPL)

Jul 22, 2025 08:50AM

Jul 22, 2025 07:03AM

Jul 15, 2025 02:47PM

Jul 7, 2025 09:38AM

Jul 7, 2025 06:36AM

Jun 25, 2025 07:04AM

Jun 20, 2025 06:09AM Cantor Fitzgerald Starts Replimune Group (REPL) at Overweight

Jun 3, 2025 10:07AM

Jun 2, 2025 06:43AM

May 22, 2025 07:17AM

Feb 13, 2025 06:48AM

Jan 21, 2025 11:00AM

Jan 21, 2025 10:32AM

Jan 21, 2025 08:05AM Replimune (REPL) Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

Dec 3, 2024 03:59PM

353,174 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All